000273938 001__ 273938
000273938 005__ 20250127091357.0
000273938 0247_ $$2pmc$$apmc:PMC11638341
000273938 0247_ $$2doi$$a10.1007/s00415-024-12747-w
000273938 0247_ $$2pmid$$apmid:39666067
000273938 0247_ $$2ISSN$$a0367-004X
000273938 0247_ $$2ISSN$$a0012-1037
000273938 0247_ $$2ISSN$$a0340-5354
000273938 0247_ $$2ISSN$$a1432-1459
000273938 0247_ $$2altmetric$$aaltmetric:172006458
000273938 037__ $$aDZNE-2024-01412
000273938 041__ $$aEnglish
000273938 082__ $$a610
000273938 1001_ $$0P:(DE-2719)9001334$$aMaass, Fabian$$b0
000273938 245__ $$aMyelin basic protein and TREM2 quantification in the CSF of patients with Multiple System Atrophy and other Parkinsonian conditions.
000273938 260__ $$aHeidelberg$$bSpringer$$c2025
000273938 3367_ $$2DRIVER$$aarticle
000273938 3367_ $$2DataCite$$aOutput Types/Journal article
000273938 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1736932949_19134
000273938 3367_ $$2BibTeX$$aARTICLE
000273938 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000273938 3367_ $$00$$2EndNote$$aJournal Article
000273938 520__ $$aIt is well known that myelin disruption and neuroinflammation are early and distinct pathological hallmarks in multiple system atrophy (MSA) as well as in idiopathic Parkinson's disease and in other atypical Parkinsonian syndromes. The objective of this study was to assess the value of non-neuronal biomarker candidates that reflect myelin disruption and neuroinflammation.Myelin basic protein (MBP) and the soluble form of TREM2 were quantified in a comprehensive movement disorder cohort from two different neurological centers, comprising a total of 171 CSF samples. Commercially available ELISA systems were employed for quantification.The results of the MBP analysis revealed a significant increase in cerebrospinal fluid (CSF) MBP levels in all atypical Parkinsonian conditions compared to PD. This differentiation was more pronounced in the MSA-c subtype compared to MSA-p. Receiver operating characteristic (ROC) analysis revealed a significant discrimination between PD and MSA (p = 0.032, AUC = 0.70), PD and DLB (p = 0.006, AUC = 0.79) and PD and tauopathies (p = 0.006, AUC = 0.74). The results of the TREM2 analysis demonstrated no significant differences between the PD and atypical Parkinsonian groups if not adjusted for confounders. After adjusting for age, sex, and disease duration, the PD group exhibited significantly higher TREM2 levels compared to the DLB group (p = 0.002).In conclusion, MBP, but not TREM2, is elevated in the CSF of not only MSA but in all atypical Parkinsonian conditions compared to idiopathic Parkinson's disease. This highlights the value of the evaluation of myelin/oligodendrocyte-associated markers in neurodegenerative movement disorders.
000273938 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000273938 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000273938 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000273938 650_7 $$2Other$$aBiomarker
000273938 650_7 $$2Other$$aCerebrospinal fluid
000273938 650_7 $$2Other$$aMultiple system atrophy
000273938 650_7 $$2Other$$aMyelin basic protein
000273938 650_7 $$2Other$$aTREM2
000273938 650_7 $$2NLM Chemicals$$aTREM2 protein, human
000273938 650_7 $$2NLM Chemicals$$aMembrane Glycoproteins
000273938 650_7 $$2NLM Chemicals$$aReceptors, Immunologic
000273938 650_7 $$2NLM Chemicals$$aBiomarkers
000273938 650_7 $$2NLM Chemicals$$aMyelin Basic Protein
000273938 650_7 $$2NLM Chemicals$$aMBP protein, human
000273938 650_2 $$2MeSH$$aHumans
000273938 650_2 $$2MeSH$$aMultiple System Atrophy: cerebrospinal fluid
000273938 650_2 $$2MeSH$$aMultiple System Atrophy: diagnosis
000273938 650_2 $$2MeSH$$aFemale
000273938 650_2 $$2MeSH$$aMale
000273938 650_2 $$2MeSH$$aAged
000273938 650_2 $$2MeSH$$aMembrane Glycoproteins: cerebrospinal fluid
000273938 650_2 $$2MeSH$$aMiddle Aged
000273938 650_2 $$2MeSH$$aReceptors, Immunologic
000273938 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000273938 650_2 $$2MeSH$$aMyelin Basic Protein: cerebrospinal fluid
000273938 650_2 $$2MeSH$$aParkinsonian Disorders: cerebrospinal fluid
000273938 650_2 $$2MeSH$$aParkinsonian Disorders: diagnosis
000273938 650_2 $$2MeSH$$aParkinson Disease: cerebrospinal fluid
000273938 650_2 $$2MeSH$$aParkinson Disease: diagnosis
000273938 650_2 $$2MeSH$$aCohort Studies
000273938 650_2 $$2MeSH$$aAged, 80 and over
000273938 7001_ $$0P:(DE-2719)9001944$$aCanaslan, Sezgi$$b1
000273938 7001_ $$0P:(DE-2719)9001486$$avan Riesen, Christoph$$b2$$udzne
000273938 7001_ $$0P:(DE-2719)2812183$$aHermann, Peter$$b3
000273938 7001_ $$0P:(DE-2719)9000287$$aSchmitz, Matthias$$b4$$udzne
000273938 7001_ $$0P:(DE-2719)9000366$$aSchulte, Claudia$$b5$$udzne
000273938 7001_ $$0P:(DE-2719)2811916$$aBrockmann, Kathrin$$b6$$udzne
000273938 7001_ $$0P:(DE-2719)2811275$$aSynofzik, Matthis$$b7$$udzne
000273938 7001_ $$0P:(DE-2719)2811350$$aBähr, Mathias$$b8$$udzne
000273938 7001_ $$0P:(DE-2719)2000058$$aZerr, Inga$$b9$$udzne
000273938 773__ $$0PERI:(DE-600)1421299-7$$a10.1007/s00415-024-12747-w$$gVol. 272, no. 1, p. 52$$n1$$p52$$tJournal of neurology$$v272$$x0367-004X$$y2025
000273938 8564_ $$uhttps://pub.dzne.de/record/273938/files/DZNE-2024-01412%20SUP.docx
000273938 8564_ $$uhttps://pub.dzne.de/record/273938/files/DZNE-2024-01412.pdf$$yOpenAccess
000273938 8564_ $$uhttps://pub.dzne.de/record/273938/files/DZNE-2024-01412%20SUP.doc
000273938 8564_ $$uhttps://pub.dzne.de/record/273938/files/DZNE-2024-01412%20SUP.odt
000273938 8564_ $$uhttps://pub.dzne.de/record/273938/files/DZNE-2024-01412%20SUP.pdf
000273938 8564_ $$uhttps://pub.dzne.de/record/273938/files/DZNE-2024-01412.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000273938 909CO $$ooai:pub.dzne.de:273938$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000273938 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001486$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000273938 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000287$$aExternal Institute$$b4$$kExtern
000273938 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000366$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000273938 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811916$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000273938 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811275$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000273938 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811350$$aExternal Institute$$b8$$kExtern
000273938 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000058$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000273938 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000273938 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000273938 9141_ $$y2025
000273938 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000273938 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000273938 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000273938 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000273938 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000273938 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROL : 2022$$d2023-10-21
000273938 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000273938 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000273938 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-21$$wger
000273938 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000273938 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000273938 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000273938 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NEUROL : 2022$$d2023-10-21
000273938 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000273938 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000273938 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000273938 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000273938 9201_ $$0I:(DE-2719)1440011-1$$kAG Zerr$$lTranslational Studies and Biomarker$$x0
000273938 9201_ $$0I:(DE-2719)1440015$$kClinical Dementia Research (Göttingen)$$lClinical Dementia Research (Göttingen)$$x1
000273938 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x2
000273938 9201_ $$0I:(DE-2719)1410002$$kAG Fischer$$lEpigenetics and Systems Medicine in Neurodegenerative Diseases$$x3
000273938 980__ $$ajournal
000273938 980__ $$aVDB
000273938 980__ $$aUNRESTRICTED
000273938 980__ $$aI:(DE-2719)1440011-1
000273938 980__ $$aI:(DE-2719)1440015
000273938 980__ $$aI:(DE-2719)1210000
000273938 980__ $$aI:(DE-2719)1410002
000273938 9801_ $$aFullTexts